Explore Hub
Comprehensive coverage and timeline for Flu. Aggregated from 59 sources with 146 articles.
146 articles · 59 sources · Coverage since 3/13/2026
How Flu coverage has developed over time.
Topics frequently covered alongside Flu.
• The FDA has approved the first mRNA-based influenza vaccine, reversing a previous decision earlier this year to decline the application's review. • The approval covers adults aged 50 to 64, while those aged 65 and older have received accelerated approval. • This decision follows a large-scale clinical trial that yielded largely favorable results, despite an unusual initial rejection by the agency.
usnews.com• The FDA has authorized Moderna’s mFlusiva, marking the first mRNA-based flu vaccine approved for use in older adults. • Separately, U.S. health officials are reviewing the nation's measles elimination status following 38 new outbreaks in 2026. • In a legal ruling, a judge designated Meta’s platforms as a "public nuisance," ordering the company to fund mental health remediation efforts.
usnews.com• South Korea's Kospi index experienced a significant surge in turbulence during June, pushing a key volatility gauge to a record-high of 96.9. • The spike was primarily driven by the flushing out of leveraged trades as market instability increased. • This event matters as it highlights the vulnerability of the South Korean market to high-leverage positions during periods of extreme price swings.
straitstimes.com• The FDA has approved the first-of-its-kind mRNA-based flu vaccine specifically for adults aged 50 and older. • This approval follows a severe 2024-25 flu season, which the CDC estimates resulted in approximately 45,000 deaths. • The shift to mRNA technology is significant as it offers the potential for more effective, rapidly adaptable vaccines compared to traditional methods.
cidrap.umn.edu• The Department of Health and Human Services (HHS) has begun implementing President Trump’s Executive Order focused on reducing prescription drug pricing. • Robert F. Kennedy Jr. appeared before the Senate for two hearings this week as part of the confirmation process to become the next HHS Secretary. • If confirmed, Kennedy would oversee critical federal functions, including vaccine regulation, disease outbreak management, and healthcare access for millions of Americans.
ajmc.comAs of 3pm Saturday, Australia had a total of 215 H5 bird flu cases nationally. Follow updatesGet our breaking news email, free app or daily news podcastThis is Adeshola Ore here to take you through today’s news as it unfolds.Let’s get into it. Continue reading...
theguardian.com
Image: Everyday Health• The FDA has approved mFlusiva, marking the first time an mRNA-based vaccine has been authorized for the prevention of influenza. • Unlike traditional flu vaccines, mRNA technology allows manufacturers to produce shots more rapidly, reducing the likelihood of a mismatch between the vaccine and circulating strains. • Medical experts, including Dr. Paul Pottinger of UW Medical Center, describe the approval as a significant advancement in public health.
everydayhealth.com
Image: PBS NewsHour• The FDA has approved Moderna's new mRNA-based flu vaccine, named mFlusiva, which is specifically intended for adults aged 50 and older. • This approval marks a shift toward using mRNA technology for seasonal influenza, moving away from traditional egg-based vaccine production methods. • The development is significant as it aims to provide more precise and potentially more effective protection against evolving flu strains.
pbs.org
Image: NBC News• The FDA approved mFlusiva, the first mRNA-based flu vaccine developed by Moderna, on Wednesday. • The vaccine is approved for adults aged 50 to 65 and those 65 and older, with late-stage trials showing it is approximately 27% more effective than standard flu shots. • This approval is significant as it applies the same messenger RNA platform used in Pfizer and Moderna's COVID-19 vaccines to seasonal influenza.
nbcnews.com
Image: Mail Online• Health officials have approved mFLUSIVA, the first mRNA-based flu vaccine developed by Moderna, which is expected to be available by the next flu season. • Clinical data indicates the shot may be 27% more effective than traditional vaccines, though side effects like fatigue and headaches occurred in up to two-thirds of patients. • The rollout follows a severe winter flu season characterized by a virulent strain that led to record-high case numbers across multiple US states.
dailymail.com